BioTech

Bayer Submits Application To EMA For Third Indication Of Darolutamide - Quick Facts

October 14, 2024 — 08:20 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Bayer announced the submission of an application to the European Medicines Agency for the oral androgen receptor inhibitor darolutamide. The company is seeking approval for the use of darolutamide in combination with androgen deprivation therapy in patients with metastatic hormone-sensitive prostate cancer.

Darolutamide is developed jointly by Bayer and Orion, a Finnish pharmaceutical company. The submission is based on positive results from the pivotal Phase III ARANOTE trial. The compound is already approved in metastatic hormone-sensitive prostate cancer, under the brand name Nubeqa, in combination with androgen deprivation therapy and docetaxel in over 80 markets around the world.

For More Such Health News, visit rttnews.com.

RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source

Tags

BioTech

Latest Articles
Data is currently not available